INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation

Omeros is facing a securities-law investigation following two negative EMA CHMP opinions on its narsoplimab application for TA-TMA, including a negative opinion after re-examination on October 16, 2026. The article reports Omeros shares fell $2.05, or 19.12%, to $8.67 on June 26 and $2.59, or 13.78%, to $16.20 on October 16; the investigation concerns whether the company and certain officers or directors engaged in securities fraud or other unlawful practices.

Analysis

The central risk is regulatory, not the existence of a law-firm investigation. A second negative CHMP opinion can weaken the value of the European opportunity and reduce Omeros’s leverage in any future regulatory or commercial discussions. Whether that changes company-wide valuation materially depends on asset concentration, cash runway, and viable paths to approval in other jurisdictions—none are established by this article and should be verified before sizing a position.

The legal headline is not evidence of fraud or a filed lawsuit. Near term, it may add volatility and raise disclosure scrutiny, but the more consequential catalyst is what the underlying regulatory record says about whether the objections can be addressed. Over 1–3 months, monitor any complaint filing, company response, and concrete next-step guidance on narsoplimab; over 6–18 months, the key question is whether additional evidence or another regulatory route can restore commercial optionality. A prolonged impasse would increase the risk that investors assign less value to the program and focus more heavily on financing runway.

Contrarian point: the repeated regulatory setback is more fundamental than the investigation headline, while the investigation itself may have limited incremental information because the negative opinions were already disclosed. Do not infer the current share price or the market’s current expectations from the historical event-day declines cited in the release. The thesis weakens if Omeros provides a credible, regulator-supported path forward or demonstrates that other assets and available capital materially reduce dependence on this indication.

Key Decisions for Investors

• Do not initiate a short solely on the Pomerantz announcement: it describes an investigation, not a finding or a confirmed class-action outcome. Reassess if a complaint is filed and alleges specific, material undisclosed facts.
• For existing OMER exposure, avoid adding until reviewing the CHMP assessment, the company’s stated route to address it, cash runway, and asset-level contribution to expected value. These are the key missing inputs for sizing downside.
• Treat any bearish position as a regulatory-risk trade, not a litigation trade: consider a defined-risk hedge only after checking option liquidity, implied volatility, and the timing of company or regulator updates. Avoid an unhedged short if those catalysts are unclear.
• Falsifiers for the negative thesis: a specific, credible regulatory pathway supported by new evidence; improving company guidance on timing or prospects; or disclosures showing that the affected indication is not material to the company’s funding outlook. Conversely, further rejection or evidence of a materially shorter cash runway would strengthen it.